11/25/2008

Johnson & Johnson said Monday that it has agreed to purchase Israel-based Omrix Biopharmaceuticals for $438 million in cash. The acquisition is expected to benefit J&J's Ethicon unit, which already owns distribution rights in the U.S. and European Union for two of Omrix's biosurgical products.

Full Story:
Forbes

Related Summaries